AHA Coding Clinic® for HCPCS - 2014 Issue 2; For your information
Reporting instructions for GAZYVA (obinutuzumab)
GAZYVA™ (obinutuzumab ) injection for intravenous use in combination with chlorambucil, was approved by the U.S. Food and Drug Administration (FDA), for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL). For facility reporting, the drug must be billed using C9399 and the drug information should be entered in the “Remarks” section of the UB-04 or electronic equivalent. Please note: As of April 1, 2014, HCPCS code C9021, Injection, obinutuzumab, 10 mg, should be used to report GAZYVA (obinutuzumab) for facility reporting. ...
To read the full article, sign in and subscribe to the AHA Coding Clinic® for HCPCS.
Thank you for choosing Find-A-Code, please Sign In to remove ads.